Bibliography
- Cowie MR , StruthersAD, WoodDA et al.: Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet350 , 1349–1353 (1997).
- Hobbs FD , DavisRC, RoalfeAK, HareR, DaviesMK, KenkreJE: Reliability of N-terminal probrain natriuretic peptide assay in diagnosis of heart failure, cohort study in representative and high risk community populations.BMJ324(7352), 1498 (2002).
- Davis M , EspinerE, RichardsG et al.: Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet343 , 440–444 (1994).
- McDonagh TA , RobbSD, MurdochDR et al: Biochemical detection of left-ventricular systolic dysfunction. Lancet351(9095), 9–13 (1998).
- Morrison LK , HarrisonA, KrishnaswamyP, KazanegraR, CloptonP, MaiselA: Utility of a rapid β-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea.J. Am. Coll. Cardiol.39(2), 202–209 (2002).
- Omland T , AakvaagA, BonarjeeVVS et al.: Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation93 , 1963–1969 (1996).
- Richards AM , NichollsG, YandleTG et al.: Plasma N-terminal probrain natriuretic peptide and adrenomedullin, new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation97 , 1921–1929 (1998).
- Tsutamoto T , WadaA, MaedaK et al.: Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure – prognostic role of brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation96 , 509–516 (1997).
- McDonagh TA , CunninghamAD, MorrisonCE et al.: Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart86(1), 21–26 (2001).
- Gardner RS , ChongV, MortonI, McDonaghTA: N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumor necrosis factor-α in patients referred for consideration of cardiac transplantation.Eur. J. Heart Fail.7(2), 253–260 (2005).
- Gardner RS , OzalpF, MurdayAJ, RobbSD, McDonaghTA: N-terminal probrain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure.Eur. Heart J.24(19), 1735–1743 (2003).
- Berger R , HuelsmanM, StreckerK et al.: B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation105(20), 2392–2397 (2002).
- Cheng V , KazanagraR, GarciaA et al.: A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure, a pilot study. J. Am. Coll. Cardiol.37(2), 386–391 (2001).
- Logeart D , ThabutG, JourdainP et al.: Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J. Am. Coll. Cardiol.43(4), 635–641 (2004).
- Gackowski A , IsnardR, GolmardJL et al.: Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur. Heart J.25(20), 1788–1796 (2004).
- Anand IS , FisherLD, ChiangYT et al.: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation107(9), 1278–1283 (2003).
- Gardner RS , ChongKS, MortonJJ, McDonaghTA: A change in N-terminal probrain natriuretic peptide is predictive of outcome in patients with advanced heart failure.Eur. J. Heart Fail.7 , 266–271 (2007).
- Lewin J , LedwidgeM, O‘LoughlinC, McNallyC, McDonaldK: Clinical deterioration in established heart failure, what is the value of BNP and weight gain in aiding diagnosis?Eur. J. Heart Fail.7(6), 953–957 (2005).
- Wu AH : Serial testing of B-type natriuretic peptide and NT-proBNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results.Am. Heart J.152(5), 828–834 (2006).
- Anderson JV , WoodruffPW, BloomSR: The effect of treatment of congestive heart failure on plasma atrial natriuretic peptide concentration, a longitudinal study.Br. Heart J.59(2), 207–211 (1988).
- Tsutsui T , TsutamotoT, MaedaK, KinoshitaM: Comparison of neurohumoral effects of short-acting and long-acting loop diuretics in patients with chronic congestive heart failure.J. Cardiovasc. Pharmacol.38(Suppl. 1) , S81–S85 (2001).
- Tsutamoto T , WadaA, MaedaK et al.: Digitalis increases brain natriuretic peptide in patients with severe congestive heart failure. Am. Heart J.134 , 910–916 (1997).
- Kobusiak-Prokopowicz M , Swidnicka-SzuszkowskaB, MysiakA: Effect of digoxin on atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP) and cyclic 3´, 5´-guanosine monophosphate (cGMP) in patients with chronic congestive heart failure.Pol. Arch. Med. Wewn.105(6), 475–482 (2001).
- Yoshimura M , YasueH, TanakaH et al.: Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br. Heart J.72 , 528–533 (1994).
- Tsutamoto T , WadaA, MaedaK et al.: Relationship between plasma levels of cardiac natriuretic peptides and soluble Fas, plasma soluble Fas as a prognostic predictor in patients with congestive heart failure. J. Card. Fail.7(4), 322–328 (2001).
- Tsutamoto T , WadaA, MaedaK et al.: Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J. Am. Coll. Cardiol.37 , 1228–1233 (2001).
- The RESOLVD Investigators: Effect of metoprolol CR in patients with ischaemic and dilated cardiomyopathy. Circulation101 , 378–384 (2000).
- Hara Y , HamadaM, ShigematsuY et al.: Effect of β-blocker on left ventricular function and natriuretic peptides in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitor. Jpn Circ. J.64(5), 365–369 (2000).
- Fung JW , YuCM, YipG et al.: Effect of β blockade (carvedilol or metoprolol) on activation of the renin–angiotensin–aldosterone system and natriuretic peptides in chronic heart failure. Am. J. Cardiol.92(4), 406–410 (2003).
- Maeda K , TsutamotoT, WadaA et al.: High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. J. Am. Coll. Cardiol.36(5), 1587–1593 (2000).
- Yu CM , FungJW, ZhangQ et al.: Improvement of serum NT-ProBNP predicts improvement in cardiac function and favourable prognosis after cardiac resynchronization therapy for heart failure. J. Card. Fail.11(Suppl. 5) , S42–S46 (2005).
- Murdoch DR , McDonaghTA, ByrneJet al.: Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration, randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am. Heart J.138 , 1126–1132 (1999).
- Troughton RW , FramptonCM, YandleTG, EspinerEA, NichollsMG, RichardsAM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations.Lancet355 , 1126–1130 (2000).
- Jourdain P , JondeauG, FunckF et al.: plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure, The STARS-BNP Multicenter Study. J. Am. Coll. Cardiol.49 , 1733–1739 (2007).